Andrew Tai1, Haily Tran2, Mary Roberts3, Nadeene Clarke2, Anne-Marie Gibson2, Suzanna Vidmar4, John Wilson5, Colin F Robertson6. 1. Department of Respiratory and Sleep Medicine, Women's and Children' Hospital, North Adelaide, Australia. Electronic address: andrew.tai@health.sa.gov.au. 2. Murdoch Children's Research Institute, Parkville, Australia. 3. Royal Children's Hospital Melbourne, Melbourne, Australia. 4. Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia. 5. Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Prahan, Australia. 6. Murdoch Children's Research Institute, Parkville, Australia; Royal Children's Hospital Melbourne, Melbourne, Australia.
Abstract
BACKGROUND: In 1964, The Melbourne Asthma Study was established to describe the spectrum and natural history of childhood asthma. OBJECTIVE: To describe the clinical and lung function outcome of childhood asthma to the age of 50 years. METHOD: Subjects were invited to complete an interviewer-administered questionnaire, skin prick testing, and measurement of lung function from the age of 7 years to the age of 50 years at 7-year intervals. RESULTS: Of 458 survivors (from the original 484 subjects at recruitment), 346 subjects (76%) participated, of whom, 197 completed lung function measurement. Asthma remission at the age of 50 years was 64% in those with wheezy bronchitis, 47% for those with persistent asthma, and 15% for those with severe asthma in childhood. Multivariable analysis identified severe asthma in childhood (odds ratio [OR] 11.9 [95% CI, 3.4-41.8]), female sex (OR 2.0 [95% CI, 1.1-3.6]), and childhood hay fever (OR 2.0 [95% CI, 1.0-4.0]) as risk factors for "current asthma" at age 50 years. There was no evidence of a difference in the rate of decline in FEV1 (mL/y, 95% CI) between the severe asthma group (15 mL/y [95% CI, 9-22 mL/y]) and all the other recruitment groups: control (16 mL/y [95% CI, 12-20 mL/y]), mild wheezy bronchitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchitis (16 mL/y [95% CI, 11-20 mL/y]), and persistent asthma (19 mL/y [95% CI, 13-24 mL/y]). CONCLUSION: The clinical and lung function outcome in adult life is strongly determined by asthma severity in childhood. The reduced lung function seen in adults is established in childhood and does not appear to decline more rapidly in adult years despite continuing symptoms.
BACKGROUND: In 1964, The Melbourne Asthma Study was established to describe the spectrum and natural history of childhood asthma. OBJECTIVE: To describe the clinical and lung function outcome of childhood asthma to the age of 50 years. METHOD: Subjects were invited to complete an interviewer-administered questionnaire, skin prick testing, and measurement of lung function from the age of 7 years to the age of 50 years at 7-year intervals. RESULTS: Of 458 survivors (from the original 484 subjects at recruitment), 346 subjects (76%) participated, of whom, 197 completed lung function measurement. Asthma remission at the age of 50 years was 64% in those with wheezy bronchitis, 47% for those with persistent asthma, and 15% for those with severe asthma in childhood. Multivariable analysis identified severe asthma in childhood (odds ratio [OR] 11.9 [95% CI, 3.4-41.8]), female sex (OR 2.0 [95% CI, 1.1-3.6]), and childhood hay fever (OR 2.0 [95% CI, 1.0-4.0]) as risk factors for "current asthma" at age 50 years. There was no evidence of a difference in the rate of decline in FEV1 (mL/y, 95% CI) between the severe asthma group (15 mL/y [95% CI, 9-22 mL/y]) and all the other recruitment groups: control (16 mL/y [95% CI, 12-20 mL/y]), mild wheezy bronchitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchitis (16 mL/y [95% CI, 11-20 mL/y]), and persistent asthma (19 mL/y [95% CI, 13-24 mL/y]). CONCLUSION: The clinical and lung function outcome in adult life is strongly determined by asthma severity in childhood. The reduced lung function seen in adults is established in childhood and does not appear to decline more rapidly in adult years despite continuing symptoms.
Authors: Torie Grant; Charles Aloe; Matthew Perzanowski; Wanda Phipatanakul; Mary E Bollinger; Rachel Miller; Elizabeth C Matsui Journal: J Allergy Clin Immunol Pract Date: 2016-12-05
Authors: Jean Bousquet; Nhân Pham-Thi; Anna Bedbrook; Ioana Agache; Isabella Annesi-Maesano; Ignacio Ansotegui; Josep M Anto; Claus Bachert; Samuel Benveniste; Mike Bewick; Nils Billo; Sinthia Bosnic-Anticevich; Isabelle Bosse; Guy Brusselle; Moïses A Calderon; G Walter Canonica; Luis Caraballo; Victoria Cardona; Ana Maria Carriazo; Eugene Cash; Lorenzo Cecchi; Derek K Chu; Elaine Colgan; Elisio Costa; Alvaro A Cruz; Wienczyslawa Czarlewski; Stephen Durham; Motohiro Ebisawa; Marina Erhola; Jean-Luc Fauquert; Wytske J Fokkens; Joao A Fonseca; Nick Guldemond; Tomohisa Iinuma; Maddalena Illario; Ludger Klimek; Piotr Kuna; Violeta Kvedariene; Désirée Larenas-Linneman; Daniel Laune; Lan T T Le; Olga Lourenço; Joao O Malva; Gert Marien; Enrica Menditto; Joaquim Mullol; Lars Münter; Yoshitaka Okamoto; Gabrielle L Onorato; Nikos G Papadopoulos; Maritta Perala; Oliver Pfaar; Abigail Phillips; Jim Phillips; Hilary Pinnock; Fabienne Portejoie; Pablo Quinones-Delgado; Christine Rolland; Ulysse Rodts; Boleslaw Samolinski; Mario Sanchez-Borges; Holger J Schünemann; Mohamed Shamji; David Somekh; Alkis Togias; Sanna Toppila-Salmi; Ioanna Tsiligianni; Omar Usmani; Samantha Walker; Dana Wallace; Arunas Valiulis; Rianne Van der Kleij; Maria Teresa Ventura; Sian Williams; Arzu Yorgancioglu; Torsten Zuberbier Journal: J Thorac Dis Date: 2019-09 Impact factor: 2.895
Authors: William T Shearer; Denise L Jacobson; Wendy Yu; George K Siberry; Murli Purswani; Suzanne Siminski; Laurie Butler; Erin Leister; Gwendolyn Scott; Russell B Van Dyke; Ram Yogev; Mary E Paul; Ana Puga; Andrew A Colin; Meyer Kattan Journal: J Allergy Clin Immunol Date: 2017-03-06 Impact factor: 10.793
Authors: Carsten Flohr; A John Henderson; Michael S Kramer; Rita Patel; Jennifer Thompson; Sheryl L Rifas-Shiman; Seungmi Yang; Konstantin Vilchuck; Natalia Bogdanovich; Mikhail Hameza; Richard M Martin; Emily Oken Journal: JAMA Pediatr Date: 2018-01-02 Impact factor: 16.193
Authors: Nara Tagiyeva; Graham Devereux; Shona Fielding; Stephen Turner; Graham Douglas Journal: Am J Respir Crit Care Med Date: 2016-01-01 Impact factor: 21.405